<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618587</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00006678</org_study_id>
    <nct_id>NCT05618587</nct_id>
  </id_info>
  <brief_title>Effect of Lithium Therapy on Long COVID Symptoms</brief_title>
  <official_title>Effect of Low-dose Lithium Therapy on Long COVID Symptoms: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess low-dose lithium's effects on several different symptoms experienced&#xD;
      by long COVID patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this double-blind, placebo-controlled study, 50 patients with long COVID will be randomly&#xD;
      assigned to either low-dose oral lithium or placebo therapy for three weeks. After the&#xD;
      double-blind study phase, all patients will be provided with lithium therapy for two&#xD;
      additional weeks. Study visits will occur at baseline and after the three-week double-blind&#xD;
      study phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>7-item questionnaire assessing fatigue severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Fog Severity Scale</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>7-item questionnaire assessing brain fog severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Day 21</time_frame>
    <description>Change in symptoms on 7-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Well-Being Scale</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>Sense of well-being over past week on 10-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-12 Health Survey (1-week modification)</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>Quality of life assessment over past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire to Continue Therapy</measure>
    <time_frame>Day 21</time_frame>
    <description>Single Yes/No question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder-2 Scale</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>2-item questionnaire assessing anxiety frequency over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache and Body Pain Bother Scale</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>2-item questionnaire assessing frequency of headaches and body pain over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>7-item questionnaire assessing insomnia severity over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sense of Smell and Taste Change Scale</measure>
    <time_frame>Day 21</time_frame>
    <description>Subjective change from baseline on a 7-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Test</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>Validated cognitive test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Recall Test</measure>
    <time_frame>Change from baseline to day 21</time_frame>
    <description>Validated cognitive test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Long COVID</condition>
  <arm_group>
    <arm_group_label>Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lithium 10mg po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identically matching the lithium pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.</description>
    <arm_group_label>Lithium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Documented or self-reported positive test for COVID-19 ≥4 weeks prior to enrollment.&#xD;
&#xD;
          2. No fever for ≥4 weeks prior to enrollment.&#xD;
&#xD;
          3. Reports fatigue and/or brain fog (i.e. concentration or memory impairment) for ≥4&#xD;
             weeks prior to enrollment on the PASC-Specific Symptom questionnaire beginning after&#xD;
             infection with COVID-19.&#xD;
&#xD;
          4. Fatigue Severity Scale (FSS) score ≥28 or Brain Fog Severity Scale (BFSS) score ≥28 at&#xD;
             baseline.&#xD;
&#xD;
          5. Beck Depression Inventory II score &lt;24.&#xD;
&#xD;
          6. No change in any psychoactive or steroid medications for ≥30 days.&#xD;
&#xD;
          7. No plan to change any psychoactive, steroid or diuretic medication for ≥5 weeks and&#xD;
             not planning on obtaining a COVID vaccine within the next 5 weeks.&#xD;
&#xD;
          8. Not using any long COVID therapies felt to be worsening the patient's symptoms or&#xD;
             starting a long COVID therapy within the next 5 weeks.&#xD;
&#xD;
          9. No history of fibromyalgia, chronic fatigue syndrome or progressive cognitive disorder&#xD;
             prior to COVID-19 infection.&#xD;
&#xD;
         10. No active medical, psychiatric or social problems that would interfere with completing&#xD;
             the study procedures in the opinion of the investigator.&#xD;
&#xD;
         11. No use of tobacco or marijuana products for &gt;6 months and no current alcohol abuse (≥4&#xD;
             drinks/day) or illicit drug use.&#xD;
&#xD;
         12. Not receiving or applying for disability payments or workman's compensation for long&#xD;
             COVID.&#xD;
&#xD;
         13. Not pregnant or nursing or planning to get pregnant over the next two months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Guttuso, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Guttuso, Jr., MD</last_name>
    <phone>716-829-5454</phone>
    <email>tguttuso@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Shepherd, NP</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Guttuso, Jr., MD</last_name>
      <phone>716-829-5454</phone>
      <email>tguttuso@buffalo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>February 10, 2023</last_update_submitted>
  <last_update_submitted_qc>February 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Thomas Guttuso</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>lithium, long COVID</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

